Daptomycin: Rationale and role in the management of skin and soft tissue infections

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue SUPPL.3, 2008, Pages 15-23

  Seaton, R A ^a  

^a GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

Author keywords

Cyclic lipopeptide; Gram positive; Mrsa; Mrse; Opat

Indexed keywords

ANTIINFECTIVE AGENT; DAPTOMYCIN;

COMMUNICABLE DISEASE; DRUG EFFECT; HUMAN; MICROBIOLOGY; PENICILLIN RESISTANCE; REVIEW; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DAPTOMYCIN; HUMANS; METHICILLIN RESISTANCE; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 55449132307     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn368     Document Type: Article

References (66)

1. Seaton RA, Nathwani D, Burton P et al. Point prevalence survey of antibiotic use in Scottish hospitals utilising the Glasgow Antimicrobial Audit Tool (GAAT). Int J Antimicrob Agents 2007; 29: 693-9.
2. Department of Health. Hospital Episode Statistics. Primary Diagnosis Summary 2005-06. http://www.dh.gov.uk/en/Publicationsandstatistics/Statistics/HospitalEpisodeStatistics/index.htm (31 March 2008, date last accessed).
3. Carratalà J, Rosón B, Fernández-Sabé N et al. Factors associated with complications and mortality in adult patients hospitalized for infectious cellulitis. Eur J Clin Microbiol Infect Dis 2003; 22: 151-7.
4. Kirkland KB, Briggs JP, Trivette SL et al. The impact of surgicalsite infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs. Infect Control Hosp Epidemiol 1999; 20: 725-30.
5. Health Protection Agency. Surgical Site Infection-National Aggregated Data on Surgical Site Infections for Hospitals that have Participated in Surgical Site Infection Surveillance Service (SSISS) between October 1997 and December 2005, 2007. http://www.hpa.org.uk/infections/topics_az/surgical_site_infection/DataList.htm (31 March 2008, date last accessed).
6. European Antimicrobial Resistance Surveillance System (EARSS). EARSS Annual Report 2006. http://www.rivm.nl/earss/Images/EARSS%202006%20Def_tcm61-44176.pdf (1 April 2008, date last accessed).
7. Huang SS, Platt R. Risk of methicillin-resistant Staphylococcus aureus infection after previous infection or colonization. Clin Infect Dis 2003; 36: 281-5.
8. Tacconelli E, De Angelis G, Cataldo MA et al. Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis. J Antimicrob Chemother 2008; 61: 26-38.
9. Lodise TP Jr, McKinnon PS, Rybak M. Prediction model to identify patients with Staphylococcus aureus bacteremia at risk for methicillin resistance. Infect Control Hosp Epidemiol 2003; 24: 655-61.
10. Graffunder EM, Venezia RA. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother 2002; 49: 999-1005.
11. Maltezou HC, Giamarellou H. Community-acquired methicillinresistant Staphylococcus aureus infections. Int J Antimicrob Agents 2006; 27: 87-96.
12. Diep BA, Chambers HF, Graber CJ et al. Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med 2008; 148: 249-57.
13. Fridkin SK, Hageman JC, Morrison M et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005; 352: 1436-44.
14. Moran GJ, Krishnadasan A, Gorwitz RJ et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355: 666-74.
15. Bone RC, Balk RA, Cerra FB et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-55.
16. Eron LJ, Lipsky BA, Low DE et al. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother 2003; 52 Suppl S1: i3-17.
17. Stevens DL, Bisno AL, Chambers HF et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41: 1373-406.
18. Darenberg J, Ihendyane N, Sjolin J et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003; 37: 333-40.
19. Gemmell CG, Edwards DI, Fraise AP et al. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 2006; 57: 589-608.
20. Nathwani D, Morgan M, Masterton RGM et al. Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community. J Antimicrob Chemother 2008; 61: 976-94.
21. Hidayat LK, Hsu DI, Quist R et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166: 2138-44.
22. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115: 674-80.
23. Sakoulas G, Moise-Broder PA, Schentag J et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42: 2398-402.
24. Soriano A, Miro O, Mensa J. Mitochondrial toxicity associated with linezolid. N Engl J Med 2005; 353: 2305-6.
25. Peeters MJ, Sarria JC. Clinical characteristics of linezolid-resistant Staphylococcus aureus infections. Am J Med Sci 2005; 330: 102-4.
26. Senneville E, Legout L, Valette M et al. Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study. J Antimicrob Chemother 2004; 54: 798-802.
27. Cubist Pharmaceuticals. Investor Relations 2008. http://www.cubist.com/investor_relations/(9 April 2008, date last accessed).
28. Alborn WE Jr, Allen NE, Preston DA. Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob Agents Chemother 1991; 35: 2282-7.
29. Lamp KC, Rybak MJ, Bailey EM et al. In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin. Antimicrob Agents Chemother 1992; 36: 2709-14.
30. Rybak MJ, Hershberger E, Moldovan T et al. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 2000; 44: 1062-6.
31. Streit JM, Jones RN, Sader HS. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms. J Antimicrob Chemother 2004; 53: 669-74.
32. Anastasiou DM, Thorne GM, Luperchio SA et al. In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin. Int J Antimicrob Agents 2006; 28: 385-8.
33. Rybak MJ, Bailey EM, Lamp KC et al. Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for Gram-positive endocarditis and bacteremia. Antimicrob Agents Chemother 1992; 36: 1109-14.
34. Dvorchik BH, Brazier D, DeBruin MF et al. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003; 47: 1318-23.
35. Wise R, Gee T, Andrews JM et al. Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers. Antimicrob Agents Chemother 2002; 46: 31-3.
36. Bush LM, Boscia JA, Wendeler M et al. In vitro postantibiotic effect of daptomycin (LY146032) against Enterococcus faecalis and methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 1989; 33: 1198-200.
37. Raad I, Hanna H, Jiang Y et al. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillinresistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother 2007; 51: 1656-60.
38. European Medicines Agency. Daptomycin: Summary of Product Characteristics 2007. http://www.emea.europa.eu/humandocs/Humans/EPAR/cubicin/cubicin.htm (31 March 2008, date last accessed).
39. Sauermann R, Rothenburger M, Graninger W et al. Daptomycin: a review 4 years after first approval. Pharmacology 2008; 81: 79-91.
40. Pai MP, Norenberg JP, Anderson T et al. Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Antimicrob Agents Chemother 2007; 51: 2741-7.
41. Mohr JF, Ostrosky-Zeichner L, Wainright DJ et al. Pharmacokinetic evaluation of single dose intravenous daptomycin in patients with thermal burn injury. Antimicrob Agents Chemother 2008; 52: 1891-3.
42. Arbeit RD, Maki D, Tally FP et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38: 1673-81.
43. Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother 2005; 55: 240-5.
44. Krige JE, Lindfield K, Friedrich L et al. Effectiveness and duration of daptomycin therapy in resolving clinical symptoms in the treatment of complicated skin and skin structure infections. Curr Med Res Opin 2007; 23: 2147-56.
45. Davis SL, McKinnon PS, Hall LM et al. Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes. Pharmacotherapy 2007; 27: 1611-8.
46. Rolston KV, Segreti J, Lamp KC et al. Cubicin Outcomes Registry and Experience (CORE) methodology. Am J Med 2007; 120: S4-5.
47. Owens RC Jr, Lamp KC, Friedrich LV et al. Postmarketing clinical experience in patients with skin and skin-structure infections treated with daptomycin. Am J Med 2007; 120: S6-12.
48. Brown J, Lamp KC, Friedrich L. Efficacy and safety of daptomycin (DAP) for the treatment of skin and skin structure infections (SSSI). In: Abstracts of the Fourth International Symposium on Resistant Gram-Positive Infections, Ontario, Canada, 2006. Abstract CPLA27.
49. Katz DE, Martone WJ. Complicated skin and skin structure infection (cSSSI) with culture confirmed Staphylococcus aureus treated with daptomycin (DAP): Cubicin Outcome Registry and Experience (CORE) 2005 interim analysis. In: Abstracts of the 2006 Annual Conference on Antimicrobial Resistance, Bethesda, MD, 2006. Poster 22, p. 25. National Foundation for Infectious Diseases, Bethesda, MD, USA.
50. Lamp KC, Friedrich L, Lindfield K. Clinical factors associated with daptomycin outcomes in skin and soft-tissue infections. In: Abstracts of the Seventeenth European Congress of Clinical Microbiology and Infectious Diseases, Munich, Germany, 2007. Poster 837, S213. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
51. Cui L, Tominaga E, Neoh HM et al. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 1079-82.
52. Boucher HW, Sakoulas G. Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis 2007; 45: 601-8.
53. Johnson KM, Lamp KC. Diabetic foot infections (DFIs) treated with daptomycin (DAP). In: Abstracts of the Forty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2007. Abstract L490, p. 398. American Society for Microbiology, Washington, DC, USA.
54. Fowler VG Jr, Boucher HW, Corey GR et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355: 653-65.
55. Rao KV, Correll TA. Evaluation of alterations of prothrombin time with the use of daptomycin. In: Abstracts of the Forty-fourth IDSA Annual Meeting, Toronto, Ontario, Canada, 2006. Abstract 218, p. 85. Infectious Diseases Society of America, Arlington, VA, USA.
56. Obeid K, Brar I, Davis S et al. Pseudohypothrombinemia during daptomycin therapy. In: Abstracts of the Forty-fourth IDSA Annual Meeting, Toronto, Ontario, Canada, 2006. Abstract 217, p. 84-5. Infectious Diseases Society of America, Arlington, VA, USA.
57. Cunha BA, Eisenstein LE, Hamid NS. Pacemaker-induced Staphylococcus aureus mitral valve acute bacterial endocarditis complicated by persistent bacteremia from a coronary stent: cure with prolonged/high-dose daptomycin without toxicity. Heart Lung 2006; 35: 207-11.
58. Lalani T, Boucher HW, Cosgrove SE et al. Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2008; 61: 177-82.
59. Lamp KC, Friedrich LV, Mendez-Vigo L et al. Clinical experience with daptomycin for the treatment of patients with osteomyelitis. Am J Med 2007; 120: S13-20.
60. Nathwani D, Seaton RA, Davey P. Key issues in the development of a non-inpatient intravenous antibiotic programme: a European perspective. Rev Med Microbiol 1997; 8: 1-11.
61. Seaton RA, Bell E, Gourlay Y et al. Nurse-led management of uncomplicated cellulitis in the community: evaluation of a protocol incorporating intravenous ceftriaxone. J Antimicrob Chemother 2005; 55: 764-7.
62. Tice AD, Rehm SJ, Dalovisio JR et al. Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA Guidelines. Clin Infect Dis 2004; 38: 1651-72.
63. Amhad QI, Mankowski M, Girish SR. Safety and tolerability of daptomycin iv bolus injections in healthy adult volunteers. In: Abstracts of the Forty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2006. Abstract A-1948, p. 31. American Society for Microbiology, Washington, DC, USA.
64. Fossaceca C. Outcomes analysis of daptomycin use in a community hospital. Adv Ther 2007; 24: 517-28.
65. Seaton RA, MacConnachie AA. Experience with daptomycin in an infectious diseases service over 1 year: utility in an outpatient parenteral antibiotic programme. Int J Antimicrob Agents 2008; 31: 492-7.
66. Martone WJ, Lindfield KC, Katz DE. Outpatient parenteral antibiotic therapy with daptomycin: insights from a patient registry. Int J Clin Pract 2008; 62: 1183-7.